MEPRO-ASPIRIN

Clinical safety rating: avoid

Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.

How it works

Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.

What the body does with it

Metabolism	Meprobamate: hepatic via CYP2C19 and glucuronidation; aspirin: hydrolyzed to salicylic acid, conjugated with glycine (salicyluric acid) and glucuronic acid.
Excretion	Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Half-life	Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Protein binding	Aspirin: Low binding (~50% to albumin). Salicylic acid: Dose-dependent; 80–90% at low concentrations, decreasing to 30–70% at high concentrations due to saturation. Mainly bound to albumin.
Volume of Distribution	Aspirin: ~0.15 L/kg (small, due to rapid hydrolysis). Salicylic acid: Dose-dependent; 0.1–0.2 L/kg at therapeutic doses; increases to 0.3–0.5 L/kg at toxic doses due to saturable protein binding. Clinical meaning: Low Vd indicates distribution primarily in extracellular fluid; higher Vd at toxic levels reflects tissue penetration.
Bioavailability	Oral: 40–50% due to first-pass metabolism in gut wall and liver (presystemic hydrolysis). Rectal: 70–100% (avoids first-pass partially). Intravenous: 100%.
Onset of Action	Oral: Analgesic effect within 30–60 minutes. Rectal: Slower, 60–120 minutes. Antiplatelet effect: Within 1 hour (irreversible COX-1 inhibition).
Duration of Action	Analgesic/antipyretic: 3–4 hours (single dose). Anti-inflammatory: 6–12 hours (multiple doses). Antiplatelet: Lifetime of platelet (7–10 days) due to irreversible acetylation.

Classification & Brands

Dosing & administration

Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. For GFR 30-60 mL/min: reduce dose by 50% (maximum 3 tablets per day).
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (maximum 3 tablets per day). Child-Pugh Class C: avoid use.
Pediatric use	Not recommended for children under 12 years due to risk of Reye's syndrome. For adolescents (12-18 years): dose based on aspirin component; do not exceed 50 mg/kg/day of aspirin.
Geriatric use	Initiate at half the standard dose (maximum 3 tablets per day) due to increased risk of gastrointestinal bleeding and renal impairment. Monitor renal function and signs of bleeding.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.

FDA category	Positive
Breastfeeding	Aspirin and meprobamate are excreted into breast milk. Meprobamate M/P ratio is approximately 4:1; avoid nursing due to potential adverse effects (e.g., sedation, poor feeding).
Teratogenic Risk	First trimester: Not recommended due to risk of miscarriage and congenital malformations (e.g., gastroschisis). Second trimester: Use with caution; associated with premature closure of ductus arteriosus and oligohydramnios. Third trimester: Contraindicated after 30 weeks due to risk of premature ductus arteriosus closure and neonatal complications (e.g., persistent pulmonary hypertension).

Warnings & precautions

■ FDA Black Box Warning

Combination product; meprobamate carries risk of dependence and withdrawal seizures; aspirin associated with Reye's syndrome in children with viral infections.

Side Effect Profile

Common Effects	fever
Serious Effects

Absolute Contraindications

Hypersensitivity to meprobamate or aspirin; active peptic ulcer; bleeding disorders; children with viral infection; severe hepatic/renal impairment; third trimester of pregnancy (aspirin); concomitant use of anticoagulants.

Clinical Precautions

Precautions

Risk of dependence and withdrawal from meprobamate; avoid in children/adolescents with viral illness (Reye's syndrome); bleeding risk (aspirin); impaired alertness; elderly and renal/hepatic impairment.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MEPRO-ASPIRIN

Clinical safety rating: avoid

Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.

How it works

Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.

What the body does with it

Metabolism	Meprobamate: hepatic via CYP2C19 and glucuronidation; aspirin: hydrolyzed to salicylic acid, conjugated with glycine (salicyluric acid) and glucuronic acid.
Excretion	Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%).
Half-life	Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life.
Protein binding	Aspirin: Low binding (~50% to albumin). Salicylic acid: Dose-dependent; 80–90% at low concentrations, decreasing to 30–70% at high concentrations due to saturation. Mainly bound to albumin.
Volume of Distribution	Aspirin: ~0.15 L/kg (small, due to rapid hydrolysis). Salicylic acid: Dose-dependent; 0.1–0.2 L/kg at therapeutic doses; increases to 0.3–0.5 L/kg at toxic doses due to saturable protein binding. Clinical meaning: Low Vd indicates distribution primarily in extracellular fluid; higher Vd at toxic levels reflects tissue penetration.
Bioavailability	Oral: 40–50% due to first-pass metabolism in gut wall and liver (presystemic hydrolysis). Rectal: 70–100% (avoids first-pass partially). Intravenous: 100%.
Onset of Action	Oral: Analgesic effect within 30–60 minutes. Rectal: Slower, 60–120 minutes. Antiplatelet effect: Within 1 hour (irreversible COX-1 inhibition).
Duration of Action	Analgesic/antipyretic: 3–4 hours (single dose). Anti-inflammatory: 6–12 hours (multiple doses). Antiplatelet: Lifetime of platelet (7–10 days) due to irreversible acetylation.

Classification & Brands

Dosing & administration

Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. For GFR 30-60 mL/min: reduce dose by 50% (maximum 3 tablets per day).
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (maximum 3 tablets per day). Child-Pugh Class C: avoid use.
Pediatric use	Not recommended for children under 12 years due to risk of Reye's syndrome. For adolescents (12-18 years): dose based on aspirin component; do not exceed 50 mg/kg/day of aspirin.
Geriatric use	Initiate at half the standard dose (maximum 3 tablets per day) due to increased risk of gastrointestinal bleeding and renal impairment. Monitor renal function and signs of bleeding.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.

FDA category	Positive
Breastfeeding	Aspirin and meprobamate are excreted into breast milk. Meprobamate M/P ratio is approximately 4:1; avoid nursing due to potential adverse effects (e.g., sedation, poor feeding).
Teratogenic Risk	First trimester: Not recommended due to risk of miscarriage and congenital malformations (e.g., gastroschisis). Second trimester: Use with caution; associated with premature closure of ductus arteriosus and oligohydramnios. Third trimester: Contraindicated after 30 weeks due to risk of premature ductus arteriosus closure and neonatal complications (e.g., persistent pulmonary hypertension).

Warnings & precautions

■ FDA Black Box Warning

Combination product; meprobamate carries risk of dependence and withdrawal seizures; aspirin associated with Reye's syndrome in children with viral infections.

Side Effect Profile

Common Effects	fever
Serious Effects